NO20045528L - MHC1R-antagonister - Google Patents
MHC1R-antagonisterInfo
- Publication number
- NO20045528L NO20045528L NO20045528A NO20045528A NO20045528L NO 20045528 L NO20045528 L NO 20045528L NO 20045528 A NO20045528 A NO 20045528A NO 20045528 A NO20045528 A NO 20045528A NO 20045528 L NO20045528 L NO 20045528L
- Authority
- NO
- Norway
- Prior art keywords
- group
- optionally substituted
- disorders
- alkyl group
- fluorine atoms
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- -1 9,10-methanoanthracene-9 (10H) -yl Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000005936 piperidyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- VUCWMAJEUOWLEY-UHFFFAOYSA-N 1-$l^{1}-azanylpiperidine Chemical compound [N]N1CCCCC1 VUCWMAJEUOWLEY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med formel I hvor R1 representerer en C1-4a1koksygruppe eventuelt substituert med ett eller flere fluoratomer eller en C1-4alkylgruppe eventuelt substituert med ett eller flere fluoratomer; n representerer 0 eller l; R2 representerer en C1-4alkylgruppe eventuelt substituert med ett eller flere fluoratomer eller en C1-4alkoksygruppe eventuelt substituert med ett eller flere fluoratomer; m representerer 0 eller l; R3 representerer H eller en C1-4a1kylgruppe; L1 representerer en alkylenkjede (CH2)r hvor r representerer 2 eller 3, eller L1 representerer en cykloheksylgruppe hvor de to nitrogenatomer som bærer henholdsvis R3 og R4, er bundet til cykloheksylgruppen enten via 1,3- eller 1,4-stillingene i cykloheksylgruppen eller L1 representerer en cyklopentylgruppe hvor de to nitrogenatomer som bærer henholdsvis R3 og R4 er bundet til cyklopentyl-gruppen via 1,3-stillingen av cyklopentylgruppen og i tillegg når R5 representerer 9,10-metanoantracen-9(10H)-yl representerer gruppen L1-N(R4)- sammen en piperidylring som er bundet til L2 gjennom piperidinyl-nitrogenet og til N-R3 via 4-stillingen i piperidylringen, med det forbehold at når R5 representerer 9,10-metanoantracen-9(10H)-yl, da er r bare 2; R4 representerer H eller en C1-4alkylgruppe eventuelt substituert med én eller flere av de følgende: en arylgruppe eller en heteroarylgruppe; L2 representerer en binding eller en alkylenkjede (CH2)s hvor s representerer 1, 2 eller 3 hvor alkylenkjeden eventuelt er substituert med én eller flere av de følgende: en C1-4alkylgruppe, fenyl eller heteroaryl; R5 representerer aryl, en heterocyklisk gruppe eller en C3-8cykloalkylgruppe som eventuelt er kondensert til en fenyl- eller til en heteroarylaruppe; så vel som optiske isomerer og racemater derav så vel som farmasøytisk akseptable salter derav, med forbehold, en fremgangsmåte for fremstilling av slike forbindelser, anvendelse av dem ved behandling av fedme, psykiatriske lidelser, kognitive lidelser, hukommelseslidelser, schizofreni, epilepsi og relaterte lidelser og nevrologiske lidelser så som demens, multippel sclerose, Parkinsons's sykdom, Huntington's chorea og Alzheimer's sykdom og smerte-relaterte lidelser, og farmasøytiske preparater inneholdende dem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202134A SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Therapeutic agents |
| PCT/GB2003/002884 WO2004004726A1 (en) | 2002-07-08 | 2003-07-04 | Mchir antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045528L true NO20045528L (no) | 2005-04-04 |
Family
ID=20288471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045528A NO20045528L (no) | 2002-07-08 | 2004-12-17 | MHC1R-antagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060247439A1 (no) |
| EP (1) | EP1528924A1 (no) |
| JP (1) | JP2006501186A (no) |
| CN (1) | CN1665502A (no) |
| AR (1) | AR040476A1 (no) |
| AU (1) | AU2003281194A1 (no) |
| BR (1) | BR0312312A (no) |
| CA (1) | CA2491835A1 (no) |
| CO (1) | CO5680403A2 (no) |
| IL (1) | IL165841A0 (no) |
| IS (1) | IS7653A (no) |
| MX (1) | MXPA05000336A (no) |
| NO (1) | NO20045528L (no) |
| PL (1) | PL374674A1 (no) |
| RU (1) | RU2004138079A (no) |
| SE (1) | SE0202134D0 (no) |
| TW (1) | TW200412957A (no) |
| WO (1) | WO2004004726A1 (no) |
| ZA (1) | ZA200500030B (no) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100451004C (zh) * | 2003-03-31 | 2009-01-14 | 大正制药株式会社 | 嘧啶衍生物 |
| US20050197350A1 (en) * | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| GB0400193D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| JP2007517868A (ja) * | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬ｉ |
| US20090036448A1 (en) * | 2004-03-30 | 2009-02-05 | Taisho Pharmecutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
| US20080090863A1 (en) * | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
| US7902356B2 (en) * | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| CA2636757A1 (en) * | 2006-01-25 | 2007-08-02 | Tesfaye Biftu | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
| MX2009003170A (es) * | 2006-09-28 | 2009-04-03 | Hoffmann La Roche | Derivados de quinolina con propiedades de union a 5-hidroxitriptamina (5-ht). |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| CN106883246B (zh) | 2009-12-04 | 2020-05-29 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| SA111320581B1 (ar) | 2010-07-06 | 2014-06-17 | استرازينيكا ايه بي | مركبات (3-(4-(أمينو ميثيل ) فينوكسي أو فينيل ثيو) أزيتيدين -1- يل) (5- فينيل -1، 3، 4- أوكسا ديازول -2- يل) ميثانون |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CA3032141A1 (en) | 2016-07-29 | 2018-02-01 | Vadim ALEXANDROV | Compounds and compositions and uses thereof |
| UA125519C2 (uk) | 2016-07-29 | 2022-04-13 | Суновіон Фармасьютікалз Інк. | Сполуки і композиції і їх застосування |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| ES2968227T3 (es) * | 2016-12-23 | 2024-05-08 | Aquinnah Pharmaceuticals Inc | Compuestos, composiciones y procedimientos de uso |
| IL268694B2 (en) | 2017-02-16 | 2023-10-01 | Sunovion Pharmaceuticals Inc | Treatment of schizophrenia |
| BR112020001433A2 (pt) | 2017-08-02 | 2020-07-28 | Sunovion Pharmaceuticals Inc. | compostos de isocromano e usos dos mesmos |
| EA202091945A1 (ru) | 2018-02-16 | 2021-01-18 | Суновион Фармасьютикалз Инк. | Соли, кристаллические формы и способы их получения |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| US20240228469A1 (en) | 2022-09-23 | 2024-07-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240217951A1 (en) | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240239767A1 (en) | 2022-12-16 | 2024-07-18 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN117486758B (zh) * | 2023-10-30 | 2025-12-26 | 南京正济医药研究有限公司 | 一种(1s,3s)-3-氨基环戊基氨基甲酸叔丁酯的制备方法 |
| TW202602886A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202539678A (zh) | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202602866A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020283A (en) * | 1958-10-20 | 1962-02-06 | Abbott Lab | Bis-lepidines |
| AU7997091A (en) * | 1990-05-30 | 1991-12-31 | American Home Products Corporation | Substituted arylsulfonamides and benzamides |
| AU2764797A (en) * | 1996-05-14 | 1997-12-05 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| PL343680A1 (en) * | 1998-04-29 | 2001-08-27 | Smithkline Beecham Plc | Quinolones used as mrs inhibitors and bactericides |
| KR100581199B1 (ko) * | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| EP1285651B1 (en) * | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| WO2002051836A1 (en) * | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| JP2004524295A (ja) * | 2001-01-26 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ｉｉ受容体アンタゴニスト |
-
2002
- 2002-07-08 SE SE0202134A patent/SE0202134D0/xx unknown
-
2003
- 2003-07-03 TW TW092118207A patent/TW200412957A/zh unknown
- 2003-07-04 PL PL03374674A patent/PL374674A1/xx not_active Application Discontinuation
- 2003-07-04 JP JP2004518963A patent/JP2006501186A/ja active Pending
- 2003-07-04 US US10/520,372 patent/US20060247439A1/en not_active Abandoned
- 2003-07-04 WO PCT/GB2003/002884 patent/WO2004004726A1/en not_active Ceased
- 2003-07-04 AU AU2003281194A patent/AU2003281194A1/en not_active Abandoned
- 2003-07-04 RU RU2004138079/04A patent/RU2004138079A/ru not_active Application Discontinuation
- 2003-07-04 CN CN038160749A patent/CN1665502A/zh active Pending
- 2003-07-04 MX MXPA05000336A patent/MXPA05000336A/es not_active Application Discontinuation
- 2003-07-04 CA CA002491835A patent/CA2491835A1/en not_active Abandoned
- 2003-07-04 EP EP03740771A patent/EP1528924A1/en not_active Withdrawn
- 2003-07-04 BR BR0312312-0A patent/BR0312312A/pt not_active IP Right Cessation
- 2003-07-08 AR AR20030102464A patent/AR040476A1/es unknown
-
2004
- 2004-12-16 IL IL16584104A patent/IL165841A0/xx unknown
- 2004-12-17 NO NO20045528A patent/NO20045528L/no unknown
-
2005
- 2005-01-03 ZA ZA200500030A patent/ZA200500030B/en unknown
- 2005-01-19 IS IS7653A patent/IS7653A/is unknown
- 2005-01-28 CO CO05007427A patent/CO5680403A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1665502A (zh) | 2005-09-07 |
| WO2004004726A1 (en) | 2004-01-15 |
| TW200412957A (en) | 2004-08-01 |
| CA2491835A1 (en) | 2004-01-15 |
| IS7653A (is) | 2005-01-19 |
| US20060247439A1 (en) | 2006-11-02 |
| AR040476A1 (es) | 2005-04-06 |
| ZA200500030B (en) | 2005-11-11 |
| BR0312312A (pt) | 2005-04-12 |
| IL165841A0 (en) | 2006-01-15 |
| RU2004138079A (ru) | 2005-08-10 |
| SE0202134D0 (sv) | 2002-07-08 |
| JP2006501186A (ja) | 2006-01-12 |
| PL374674A1 (en) | 2005-10-31 |
| CO5680403A2 (es) | 2006-09-29 |
| EP1528924A1 (en) | 2005-05-11 |
| AU2003281194A1 (en) | 2004-01-23 |
| MXPA05000336A (es) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045528L (no) | MHC1R-antagonister | |
| AR017236A1 (es) | Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar | |
| EP2297120A1 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
| NO20084302L (no) | 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer | |
| AU2001272476A1 (en) | Piperidines for use as orexin receptor antagonists | |
| ATE381542T1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
| MXPA03006918A (es) | Compuestos heterociclicos fusionados. | |
| WO2006046031A8 (en) | Pharmaceutical compounds | |
| NO20061419L (no) | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser | |
| NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
| EP1479684A4 (en) | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME | |
| DE69835877D1 (de) | Trizyklische verbindungen | |
| WO2008107677A3 (en) | Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders | |
| ATE180780T1 (de) | 2-(piperidin-4-yl, pyridin-4-yl und tetrahydropyridin-4-yl)-benzofuran-7-carbamat derivate, ihre herstellung und verwendung als acetylcholinesterase inhibitoren | |
| MY145746A (en) | Heterocyclic substituted pyridine derivatives and antifungal agent containing same | |
| MX2009009384A (es) | Malonamidas como antagonistas de orexina. | |
| WO2002028853A1 (en) | Benzylamine compound, process for producing the same, and intermediate therefor | |
| NO20080025L (no) | Pyrazolderivater som CB1 modulatorer | |
| MXPA04002569A (es) | H6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan citocinas inflamatorias. | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
| MXPA04000978A (es) | Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas. | |
| WO1999021848A3 (en) | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands | |
| MX2007003922A (es) | Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central. |